Answered

At Westonci.ca, we connect you with the answers you need, thanks to our active and informed community. Find reliable answers to your questions from a wide community of knowledgeable experts on our user-friendly Q&A platform. Join our Q&A platform to connect with experts dedicated to providing accurate answers to your questions in various fields.

About 40% of metastatic melanoma patients treated with anti-PD-1 or anti-PD-L1 therapy develop some antitumor immune responses that delay cancer progression or even lead to complete remissions. Why do you think that some patients respond to checkpoint blockade therapy, while others do not?

Sagot :

Thank you for your visit. We're committed to providing you with the best information available. Return anytime for more. Thank you for visiting. Our goal is to provide the most accurate answers for all your informational needs. Come back soon. We're here to help at Westonci.ca. Keep visiting for the best answers to your questions.